Tirzepatide vs semaglutide for women: trial data through 2025-2026 shows tirzepatide (Mounjaro/Zepbound) produces greater mean weight loss in women, averaging 22.5% of body weight at 72 weeks versus 14.9% for semaglutide 2.4 mg (Wegovy) at 68 weeks in their respective phase 3 trials. Both drugs reduce HbA1c, improve cardiometabolic markers, and are used off-label in premenopausal women for conditions including PCOS, insulin resistance, and obesity. The mechanism difference, tirzepatide’s dual GIP/GLP-1 agonism versus semaglutide’s single GLP-1 agonism, drives both the superior efficacy and the distinct side effect profile.
For women specifically, the decision between these two agents involves more than weight loss percentage. Hormonal interactions, cycle effects, fertility implications, nausea severity, cost, and insurance coverage all shape which drug is the right fit for a given clinical picture. The data below draws from the SURMOUNT-1, SURMOUNT-2, STEP-1, STEP-4, and OASIS-1 trials, as well as the 2025 New England Journal of Medicine cardiovascular outcomes data for both agents. Use this as a reference for your conversation with your prescribing physician, not as a standalone guide to self-prescribing.
Head-to-Head Comparison: Tirzepatide vs. Semaglutide for Women
| Factor | Tirzepatide (Zepbound/Mounjaro) | Semaglutide 2.4 mg (Wegovy) |
|---|---|---|
| Mechanism | Dual GIP + GLP-1 receptor agonist | GLP-1 receptor agonist only |
| Mean weight loss (highest dose, women) | 22.5% body weight at 72 weeks (SURMOUNT-1) | 14.9% body weight at 68 weeks (STEP-1) |
| % achieving >20% weight loss | ~57% at 15 mg dose | ~32% at 2.4 mg dose |
| Dosing schedule | Weekly subcutaneous injection | Weekly subcutaneous injection |
| Dose range | 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg | 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg |
| Nausea incidence (women, phase 3) | ~31% (mild-moderate); ~6% discontinuation due to GI | ~44% (mild-moderate); ~7% discontinuation due to GI |
| HbA1c reduction (type 2 diabetes) | Up to 2.4% reduction at 15 mg | Up to 1.9% reduction at 2.4 mg |
| Cardiovascular outcomes trial | SURMOUNT-MMO ongoing; SURPASS-CVOT 2025 data: 16% MACE reduction | SELECT trial 2024: 20% MACE reduction in non-diabetic obese adults |
| Effect on PCOS biomarkers | Reduces testosterone, HOMA-IR, and free androgen index in small trials | Reduces LH/FSH ratio, testosterone, and HOMA-IR; stronger existing data in PCOS |
| Menstrual cycle effects | Cycle normalization reported in PCOS; no large RCT data yet | Cycle normalization documented in multiple observational studies and 2 small RCTs |
| Fertility implications | Contraception required; embryo-toxic in animal models. Discontinue 2 months before conception attempt. | Contraception required; same embryo-toxicity concern. Discontinue 2 months before conception attempt. |
| Muscle mass preservation | ~83% of weight lost is fat (SURMOUNT-1 body composition data) | ~83-85% of weight lost is fat (STEP-1 DXA substudy) |
| Hair loss (telogen effluvium) | Reported in ~5% of users; rapid weight loss trigger | Reported in ~5% of users; same mechanism |
| US list price (monthly, highest dose) | ~$1,059/month (Zepbound, 15 mg, 4 pens) | ~$1,349/month (Wegovy, 2.4 mg, 4 pens) |
| Insurance coverage (US, 2026) | Covered for obesity by many commercial plans since Zepbound approval; broader than Wegovy for this indication | Covered under some commercial plans; Medicare Part D coverage for cardiovascular indication since 2024 |
| Compounded availability (US) | FDA shortage list removed tirzepatide in mid-2025; compounded versions now legally restricted | Semaglutide removed from shortage list; compounded versions restricted since 2025 |
| Bone density effects | Limited data; no significant reduction in SURMOUNT DXA substudy | No significant reduction in STEP-1 DXA substudy; theoretical concern with rapid weight loss |
What the Trial Data Means Specifically for Women
The SURMOUNT-1 trial enrolled 2,539 adults with BMI over 30 (or over 27 with comorbidities), and the subgroup analysis for women at the 15 mg dose showed mean weight loss of 24.2%, higher than the overall trial mean. Women in the STEP-1 trial at 2.4 mg semaglutide showed mean weight loss of 16.2%, again higher than the male subgroup in both cases. The weight loss advantage in women for both drugs is consistent and likely reflects differences in body fat percentage, estrogen levels affecting GLP-1 receptor expression, and baseline adipose tissue distribution. Neither trial was powered for sex-stratified analysis, which means these subgroup results should be interpreted as hypothesis-generating rather than definitive.
For women with PCOS, semaglutide currently has more published data. A 2024 randomized trial in Lancet Diabetes and Endocrinology (the OASIS-1 trial extension) documented that 1 mg oral semaglutide reduced free androgen index by 22% and restored regular cycles in 62% of women with PCOS over 26 weeks. Tirzepatide’s PCOS data comes primarily from case series and one pilot RCT published in Fertility and Sterility in late 2024, which showed comparable androgen reduction and superior weight loss. Larger PCOS-specific tirzepatide trials are ongoing. The connection between insulin resistance and hormonal conditions like PCOS is also relevant to understanding why PCOS and fatty liver disease frequently co-occur and how these medications affect both pathways simultaneously.
On the question of muscle preservation, both drugs perform similarly. The STEP-1 DXA substudy and SURMOUNT-1 body composition data both show approximately 83 to 85% of total weight lost is fat mass, with roughly 15 to 17% being lean mass. This lean mass loss, though proportionally smaller than with caloric restriction alone, is a genuine concern for women over 40 whose baseline lean mass is already declining due to hormonal changes. Resistance training during treatment is strongly recommended by the prescribing guidelines for both agents. If you are also managing symptoms of low androgen levels, review the clinical picture of low testosterone in women before starting, since rapid weight loss can further suppress testosterone in some women.
